Under the leadership of Joshua B. Bederson, MD, Professor and Chair of Neurosurgery, Mount Sinai Health System is an internationally recognized leader in neurosurgery and continues to make a lasting global impact on neurosurgical outcomes, research, and education. As the largest unified and integrated neurosurgery department in New York City—with services provided throughout Manhattan, Queens, and Long Island—we provide more New Yorkers with neurosurgery care than any other health system in the city.
Mount Sinai’s Department of Neurosurgery is at the forefront of the rapid transformation of clinical practice driven by stunning new advances in technology and groundbreaking research. Neurology and Neurosurgery at The Mount Sinai Hospital is nationally ranked by U.S. News & World Report® for 2024-25, Mount Sinai aims to educate clinicians on the treatment of patients’ challenging conditions with the insight and expertise of its world-renowned surgeons. Mount Sinai Morningside/Mount Sinai West is ranked No. 29 in the nation for Neurology and Neurosurgery by U.S. News & World Report® for 2024-25.
Led by Barbara Vickrey, MD, MPH, Professor and Chair, the Department of Neurology at the Icahn School of Medicine at Mount Sinai is equally robust in patient care, education, and research. The Department's foundational mission includes training the next generation of clinicians, clinician-educators, clinician-investigators, and future leaders in medicine, as well as providing high-quality patient care to all New York City communities. A unique blend of personalized patient care integrated with groundbreaking research teams and technology is instrumental in the pursuit of improving outcomes in the treatment of Parkinson’s disease, epilepsy, multiple sclerosis, stroke, Alzheimer’s disease, and many other neurological disorders, referred from within our expansive health system, as well as from around the world.
Under the leadership of Joshua B. Bederson, MD, Professor and Chair of Neurosurgery, Mount Sinai Health System is an internationally recognized leader in neurosurgery and continues to make a lasting global impact on neurosurgical outcomes, research, and education. As the largest unified and integrated neurosurgery department in New York City—with services provided throughout Manhattan, Queens, and Long Island—we provide more New Yorkers with neurosurgery care than any other health system in the city.
Mount Sinai’s Department of Neurosurgery is at the forefront of the rapid transformation of clinical practice driven by stunning new advances in technology and groundbreaking research. Neurology and Neurosurgery at The Mount Sinai Hospital is nationally ranked by U.S. News & World Report® for 2024-25, Mount Sinai aims to educate clinicians on the treatment of patients’ challenging conditions with the insight and expertise of its world-renowned surgeons. Mount Sinai Morningside/Mount Sinai West is ranked No. 29 in the nation for Neurology and Neurosurgery by U.S. News & World Report® for 2024-25.
Led by Barbara Vickrey, MD, MPH, Professor and Chair, the Department of Neurology at the Icahn School of Medicine at Mount Sinai is equally robust in patient care, education, and research. The Department's foundational mission includes training the next generation of clinicians, clinician-educators, clinician-investigators, and future leaders in medicine, as well as providing high-quality patient care to all New York City communities. A unique blend of personalized patient care integrated with groundbreaking research teams and technology is instrumental in the pursuit of improving outcomes in the treatment of Parkinson’s disease, epilepsy, multiple sclerosis, stroke, Alzheimer’s disease, and many other neurological disorders, referred from within our expansive health system, as well as from around the world.
Mount Sinai, long a leader in epilepsy care and research, is expanding its partnerships with independent neurologists and primary care physicians across the United States, building on its expertise in new diagnostics and successful strategies ...
It has been an outstanding year of achievements on the clinical, research, and innovation fronts. Read on to learn how—and where—our Mount Sinai teams excelled.
A blood biomarker study focusing on Asian populations will provide better ways to detect, diagnose, and treat Alzheimer’s disease in a group that has been underrepresented in research of the neurodegenerative disease.
Migraine headache treatment was revolutionized in recent years by new medicines and approaches, led by calcitonin gene-related peptide (CGRP) antagonists, oral preventive medications, and neuromodulation devices. However, migraine is a ...
Using an advanced artificial intelligence tool, researchers at the Icahn School of Medicine at Mount Sinai have identified rare coding variants in 17 genes that shed light on the molecular basis of coronary artery disease (CAD), the leading ...
Researchers at the Icahn School of Medicine at Mount Sinai have made a significant breakthrough in Alzheimer’s disease research by identifying a novel way to potentially slow down or even halt disease progression. The study, which focuses ...
Researchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in ...
In this video, Joohi Jimenez-Shahed, MD, describes the use of surgical and device-assisted therapies such as deep brain stimulation, focused ultrasound, and carbidopa/levodopa pumps for the management of patients with advanced Parkinson’s disease.
The documentary film “Matter of Mind, My Parkinson’s” features Brian Kopell, MD, Director of the Center for Neuromodulation at Mount Sinai West, and his team.
How Mount Sinai Neurology and Neurosurgery Are Changing the Game
It has been an outstanding year of achievements on the clinical, research, and innovation fronts. Read on to learn how—and where—our Mount Sinai teams excelled.
Scientists at the Icahn School of Medicine at Mount Sinai uncovered a previously unrecognized role of microglia autophagy and senescence in Alzheimer’s disease pathology. The study, published in Nature Cell Biology, identified a novel ...
Amyloidosis is a rare disease that is difficult to diagnose, often resulting in missed opportunities for early treatment that could have deterred damage to major organs, such as the heart, nervous system, kidneys, and gastrointestinal tract.
People with neurofibromatosis type 1 (NF1) develop cutaneous tumors that can significantly impair their quality of life. Mount Sinai’s Rebecca M. Brown, MD, PhD, is using a pioneering approach to surgically remove tumors during routine ...
Learn about current best practices in the management of headache, and the latest research on the potential relationship between gender-affirming hormone therapy and headache.
This collection of eight articles brings together neuroscientists, psychiatrists, and geneticists, among others, to unravel the pathophysiology of brain dysfunction.
The Mount Sinai Hospital's departments of Neurology and Neurosurgery were top performers in both U.S. News & World Report and Newsweek rankings for 2022–2023, and in National Institutes of Health (NIH) research funding.
Mount Sinai researchers are characterizing subtypes of dopamine neurons by deploying single-cell RNA sequencing to uncover the molecular mechanisms of vulnerability and resilience, and to identify neuroprotective strategies.
In understanding the pathogenesis of multiple sclerosis and other autoimmune diseases of the central nervous system, there is great interest in the role of an intermediary compartment of channels between the bloodstream and the central ...
Overall, the authors say the study’s findings, while preliminary, may be used as a guide in the diagnostic evaluation of presumed central nervous system inflammation in which clinical history alone is not sufficient to narrow the differential.
A Mount Sinai-led team of international investigators, in collaboration with Novartis, the University of Oxford, and other renowned scientists in the field, has gained new understanding on the role of relapses on long-term outcomes, the ...
Mice exposed to World Trade Center dust exhibit a significant impairment in spatial recognition and short- and long-term memory, as well as changes in genes related to immune-inflammatory responses and blood-brain barrier disruption...
Anna Pace, MD, discusses a new study that sought to describe migrainous headache frequency and severity and the relationship between trauma and discrimination in a sample of sexual and/or gender minority adults.
A new study links a gene called inositol polyphosphate-5-phosphatase D (INPP5D) which is concentrated in the brain’s cleanup cells known as microglia, to the inflammation that has increasingly emerged as a key mechanism contributing to Alzheimer’s disease.
Past social trauma is encoded by a population of stress/threat-responsive brain cells that become hyperactivated during subsequent interaction with non-threatening social targets.
White matter in the brain that was previously implicated in animal studies has now been suggested to be specifically impaired in the brains of people with addiction to cocaine or heroin.
Benjamin Kummer, MD, talks about telestroke and the future of teleneurology at a virtual session hosted by the American Medical Association (AMA) in collaboration with the American Academy of Neurology (AAN).
A conversation with Nathalie Jetté, MD, MSc, Professor of Neurology, and Population Health Science and Policy, and the Bludhorn Professor of International Medicine at the Icahn School of Medicine at Mount Sinai.
Mount Sinai's Jessica Robinson-Papp, MD, MS, and Mary Catherine George, PhD, are the principal investigator (PI) and Co-PI, respectively, of the Early Phase Pain Investigational Clinical Network (EPPIC-Net) “Platform Protocol to Assess ...
Research led by Mount Sinai has uncovered—for the first time—that eating healthy foods is associated with greater brain integrity, as detected by MRI imaging in people diagnosed with MS within the previous five years.
Neuroscientists and engineers developing novel nerve stimulation devices to improve or restore impaired organ function now have access to a powerful and long awaited tool for overcoming the technical challenges of the past.
It has been an outstanding year of achievements on the clinical, research, and innovation fronts. Read on to learn how—and where—our Mount Sinai teams excelled.
Mount Sinai researchers have discovered for the first time a neural mechanism for memory integration that stretches across both time and personal experience.
Neurosurgeons and neuroscientists at the Icahn School of Medicine at Mount Sinai are the first in New York State to study a new brain-computer interface (BCI) technology that aims to record and map a large area of the brain’s surface, ...
Researchers from the Icahn School of Medicine at Mount Sinai have shed valuable light on the nuanced functions and intricate regulatory methods of RNA editing, a critical mechanism underlying brain development and disease.
Mount Sinai physicians are at the forefront of advancing the use of vagus nerve stimulation (VNS) for chronic ischemic stroke survivors who pursued physical therapy yet lack significant recovery in hand and arm function. They are also ...
New research conducted by researchers from the Icahn School of Medicine at Mount Sinai in collaboration with an international team of neuroscientists, clinicians, and computational scientists reveals, for the first time, the roles of the ...
A team of Mount Sinai surgeons, led by neurosurgeon Jeremy M. Steinberger, MD, Director of Minimally Invasive Spine Surgery for the Department of Neurosurgery, presents the first reported case of a fully robotic anterior and posterior ...
A Mount Sinai Health System neurosurgeon demonstrates how using patient-specific diffusion tensor imaging (DTI) tractography in combination with high-frequency focused ultrasound (HiFU) can improve safety and outcomes in certain patients.
The Mount Sinai Hospital's departments of Neurology and Neurosurgery were top performers in both U.S. News & World Report and Newsweek rankings for 2022–2023, and in National Institutes of Health (NIH) research funding.
Using a strategy devised by its biomedical incubator, Mount Sinai BioDesign, surgeons can now assess and quantify the extent of embolization through an analysis of an additional MRI sequence following embolization and preceding surgical resection.
A 40-year old male presents with treatment-resistant OCD to Mount Sinai. His symptoms began as tics in childhood, which progressed into fears of self-harm and harming others, and, later, compulsive urges to poke his eyes.
Assessing the full impact of deep brain stimulation in patients with Parkinson’s disease and Tourette syndrome has been limited to observations made during implantation and through patient follow-ups.
With ongoing studies on both MIS sICH evacuation and percutaneous PE thrombectomy, Mount Sinai reports a notable case of combined percutaneous PE thrombectomy and MIS sICH evacuation with remarkable results.
Mount Sinai, already a leader in minimally invasive spine surgery and the use of virtual and augmented reality and robotics, has adopted a new real-time, radiation-free navigation technology that enhances accuracy, anatomical verification, ...
In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, the Mount Sinai Health System announced the launch of the Comprehensive Center for Surgical Innovation, ...
A baby born with an imperforate anus, VACTERL syndrome, and a large lipomyelomeningocele with tethered spinal cord received successful care at Mount Sinai.
Individuals with cocaine use disorder exhibit gene expression changes in two brain regions: the nucleus accumbens, a region associated with reward, and the caudate nucleus, a region mediating habit formation...
The Icahn School of Medicine at Mount Sinai has launched a neurometabolism program that combines basic science research with a clinic dedicated to the care of patients with brain metabolic diseases.
Researchers from the Icahn School of Medicine at Mount Sinai have learned that the way the brain processes the complex emotion of regret may be linked to an individual’s ability to cope with stress, and altered in psychiatric disorders like depression.
In a move that has the potential to change the future of surgery, advance quality care, and bring economic growth to New York City, Mount Sinai Health System announced today the launch of the Comprehensive Center for Surgical Innovation (CCSI).
An 85-year-old female with a high-risk vascular anatomy from diffuse fibromuscular dysplasia presents at Mount Sinai Queens with disabling neurological deficits from emergent large vessel occlusion ischemic stroke. She undergoes endovascular ...
A 2-month-old female neonate presented to Mount Sinai Kravis Children’s Hospital for life-saving treatment of dural sinus malformation, hydrocephalus, and acute intracranial hemorrhage.
Mount Sinai's in-house incubator for biomedical innovation, Mount Sinai BioDesign, has two new products on the road to commercialization, underscoring its value as one of the most productive and entrepreneurial programs of its type in the nation.
Constantinos G. Hadjipanayis, MD, PhD, shows how intraoperative visualization, with use of a 3D exoscope, 5-ALA fluorescence, neuronavigation, and diffusion tensor imaging fiber tracking, helped safely resect a high-grade glioma in a 33-year-old.
The Mount Sinai Hospital's departments of Neurology and Neurosurgery were top performers in both U.S. News & World Report and Newsweek rankings for 2021–2022, and in National Institutes of Health (NIH) research funding.
THE MOUNT SINAI HOSPITAL’S departments of Neurology and Neurosurgery were top performers in both U.S. News & World Report and Newsweek rankings for 2021–2022, and in National Institutes of Health (NIH) research funding.
